The National Comprehensive Cancer Network (NCCN®) has announced the election of Matt Kalaycio, MD, FACP, as Chair of the Board of Directors, with Christopher H. Lieu, MD, elected as Vice-Chair, succeeding Dr. Kalaycio in the position he has held since 2022.
“The exemplary leadership from our Board of Directors is invaluable as NCCN defines and advances high-quality, high-value, patient-centered cancer care around the world,” said NCCN Chief Executive Officer Crystal S. Denlinger, MD, FACP, who took on the role in October 2023. “Their steady guidance during a transitional time helps us maintain our highly trusted, continuously updated, evidence-based, expert consensus recommendations for cancer care, which were accessed more than 15 million times in 2023 alone. I look forward to working even more closely with Matt and Chris and relying on the substantial expertise, caring, and leadership they bring to these positions.”
Matt Kalaycio, MD, FACP
Christopher H. Lieu, MD
Crystal S. Denlinger, MD, FACP
Dr. Kalaycio is a leading expert in hematology and medical oncology, specializing in the treatment of leukemia, hematopoietic cell transplantation, and chimeric antigen receptor T-cell therapy. He is Vice-Chair of Cleveland Clinic Cancer Institute and Professor of medicine at Cleveland Clinic Lerner College of Medicine of Case Western Reserve University.
“NCCN is committed to ensuring that all cancer patients receive the latest evidence-based treatment options by not only informing health-care providers of available treatments, but also offering education and support to the patients and their caregivers,” said Dr. Kalaycio. “As I take on the role of Chair of the NCCN Board of Directors, I eagerly anticipate further advancing the organization’s mission.”
Dr. Lieu is Associate Professor, Co-Director of Gastrointestinal Medical Oncology, and Associate Director for Clinical Research at the University of Colorado Cancer Center. His research focuses on drug development for gastrointestinal cancers, including novel strategies for treating and preventing colorectal cancer in young adults. Dr. Lieu is also a member of the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Panel for Neuroendocrine Tumors and serves on the U.S. Food and Drug Administration Oncologic Drugs Advisory Committee.
“I am very honored to serve as the Vice-Chair of the NCCN Board of Directors,” said Dr. Lieu.
